Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established ...
November 12 2018 - 7:00AM
Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology
company and maker of V-Go® Wearable Insulin Delivery device, a
simple, all-in-one,wearable insulin delivery option for patients
with diabetes, announced today a poster titled “Relationship
between Baseline BMI and Clinical Outcomes with V-Go® Wearable
Insulin Delivery Device in Patients with Type 2 Diabetes Previously
Prescribed Basal-Bolus Regimens” was presented over the weekend at
the 18th Annual Diabetes Technology Meeting in North Bethesda,
Maryland.
Obesity has been associated with higher insulin requirements in
patients with type 2 diabetes, therefore evaluating the impact of
body mass index (BMI), a measurement of body fat, on insulin
treatment is important. V-Go wearable delivery device has
demonstrated lower A1c levels with less insulin; however, the
effect of BMI on insulin dose and change in A1c with V-Go has not
been evaluated. This study investigated the impact to A1c and Total
Daily Dose (TDD) in patients with type 2 diabetes who were switched
from prior insulin regimens to V-Go when findings were stratified
by established BMI strata (normal-weight, overweight, obesity class
I, II or III). Clinical outcomes across all five BMI strata were
evaluated after a mean of three months of V-Go use. The
findings demonstrated all strata benefited from a reduction in A1c
(range of -0.7% to 1.5%) and reduction in TDD (range of -17 units
per day to -38 units per day) compared to baseline.
“We are excited by the findings of this study,” said John
Timberlake, President and Chief Executive Officer of Valeritas. “We
have taken our growing portfolio of positive clinical data a step
further, demonstrating the use of V-Go can clinically benefit
patients with type 2 diabetes across all BMI strata.”
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company
focused on improving health and simplifying life for people
with diabetes by developing and commercializing innovative
technologies. Valeritas’ flagship product, V-Go® Wearable
Insulin Delivery device, is a simple, affordable,
all-in-one basal-bolus insulin delivery option for patients
with type 2 diabetes that is worn like a patch and
can eliminate the need for taking multiple daily shots. V-Go
administers a continuous preset basal rate of insulin over 24
hours, and it provides discreet on-demand bolus dosing at
mealtimes. It is the only basal-bolus insulin delivery device on
the market today specifically designed keeping in mind the needs of
type 2 diabetes patients. Headquartered in Bridgewater, New Jersey,
Valeritas operates its R&D functions in Marlborough,
Massachusetts.
More information is available at www.valeritas.com and
our Twitter feed at www.twitter.com/Valeritas_US.
Forward-Looking Statements
This press release may contain forward-looking statements.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to Valeritas technologies,
business and product development plans and market information.
Actual results could differ from those projected in any
forward-looking statements due to numerous factors. Such factors
include, among others, the ability to raise the additional funding
needed to continue to pursue Valeritas’ business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, the ability to
commercialize the V-Go® Wearable Insulin Delivery device with
limited resources, competition in the industry in which Valeritas
operates and overall market conditions. Any forward-looking
statements are made as of the date of this press release, and
Valeritas assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by law. Investors should consult all of the information
set forth herein and should also refer to the risk factor
disclosure set forth in the reports and other documents Valeritas
files with the SEC available at http://www.sec.gov.
Investor Contacts:Lynn Pieper Lewis or Greg ChodaczekGilmartin
Group646-924-1769ir@valeritas.com
Media Contact:Kevin KnightKnight Marketing Communications,
Ltd.(206) 451-4823pr@valeritas.com
Valeritas (NASDAQ:VLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valeritas (NASDAQ:VLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024